XML 39 R27.htm IDEA: XBRL DOCUMENT v3.4.0.3
Significant Accounting Policies, Stock-Based Compensation Expense (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Stock-based Compensation Expense [Abstract]    
Stock-based compensation expense $ 20,103 $ 13,305
Stock Options [Member]    
Unrecognized Compensation Expense [Abstract]    
Unrecognized compensation expense related to non-vested stock options $ 88,900  
Weighted average period for recognition 1 year 6 months  
Stock Options [Member] | Board of Directors [Member]    
Stock-based Compensation Expense [Abstract]    
Options granted (in shares) 0 0
RSUs [Member]    
Stock-based Compensation Expense [Abstract]    
Vesting period 4 years  
Unrecognized Compensation Expense [Abstract]    
Unrecognized compensation cost related to non-vested RSUs $ 23,800  
Weighted average period for recognition 1 year 8 months 12 days  
RSUs [Member] | Employees [Member]    
Stock-based Compensation Expense [Abstract]    
Weighted-average grant date fair value (in dollars per share) $ 43.88  
RSUs [Member] | Board of Directors [Member]    
Stock-based Compensation Expense [Abstract]    
Units granted (in shares) 0 0
Research, Development and Patent Expenses [Member]    
Stock-based Compensation Expense [Abstract]    
Stock-based compensation expense $ 14,770 $ 10,486
General and Administrative [Member]    
Stock-based Compensation Expense [Abstract]    
Stock-based compensation expense 5,333 2,819
Akcea Therapeutics [Member]    
Stock-based Compensation Expense [Abstract]    
Stock-based compensation expense $ 3,200 $ 600